RxDoctor Payments Data

Rachel Roberts, APRN

Psychiatric/Mental Health · Bowling Green, KYNPI 1912545468

Payments from drug & device makers

$4,214in general payments, 2019–2025

Across 280 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$620
  • Alkermes, Inc.$470
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$460
  • Lundbeck LLC$356
  • Teva Pharmaceuticals USA, Inc.$319
  • AbbVie$312
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$4,16799%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,214 in reported general payments places this provider in the 85th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,222
Medicare patients
22
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole22$61,395
AuvelityDextromethorphan Hbr/Bupropion17$21,968
TrintellixVortioxetine Hydrobromide13$5,866
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$3,558
Vilazodone Hcl11$2,299
Aripiprazole14$2,205
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$1,561
Clozapine11$1,385
Methylphenidate ErMethylphenidate Hcl14$1,192
Modafinil22$984
Hydroxyzine Hcl22$689
Buspirone Hcl40$644
Lurasidone Hcl13$281
Lamotrigine39$254
Nortriptyline Hcl11$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$169$61,39522 claims
Axsome Therapeutics, Inc.Auvelity$42$21,96817 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$254$5,86613 claims
Almatica Pharma LLCSertraline Hcl$32$14526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →